Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP)

Q4 2019 13F Holders as of 12/31/2019

Type / Class: Equity / Ordinary Shares
Shares outstanding: 1.57B
Number of holders: 33
Total 13F shares, excl. options: 64.9M
Shares change: -3.23M
Total reported value, excl. options: $77.8M
Value change: -$4.19M
Number of buys: 15
Number of sells: -20
Price: $1.20

Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) as of Q4 2019

46 filings reported holding ADAP - Adaptimmune Therapeutics PLC - Ordinary Shares as of Q4 2019.
Adaptimmune Therapeutics PLC - Ordinary Shares (ADAP) has 33 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 64.9M shares of 1.57B outstanding shares and own 4.13% of the company stock.
Largest 10 shareholders include Matrix Capital Management Company, LP (28M shares), NEA Management Company, LLC (15.8M shares), Capital World Investors (6.79M shares), BAILLIE GIFFORD & CO (4.29M shares), FMR LLC (1.58M shares), RENAISSANCE TECHNOLOGIES LLC (1.47M shares), ORBIMED ADVISORS LLC (1.35M shares), Man Group plc (1.08M shares), Polygon Management Ltd. (857K shares), and Rock Springs Capital Management LP (800K shares).
This table shows the top 33 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.

Investor	Option	Weight %	Change %	Value $	* Price $	Shares	Share Change	Activity	Report Period

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.